Guselkumab’s safety profile consistent regardless TNF-inhibitor use in psoriatic arthritis

The 2-year safety profile of guselkumab appears consistently favorable across patients with psoriatic arthritis who are either naïve or experienced with TNF inhibitors, according to data published by The Journal of Rheumatology.
“Guselkumab, a monoclonal antibody that selectively inhibits interleukin (IL)-23 p19, was the first agent in its class approved for patients with active PsA,” Proton Rahman, MD, FRCPC, of the Craig L. Dobbin Genetics Research Center at Memorial University of Newfoundland, in Canada, and colleagues wrote. “The majority of these patients were

The 2-year safety profile of guselkumab appears consistently favorable across patients with psoriatic arthritis who are either naïve or experienced with TNF inhibitors, according to data published by The Journal of Rheumatology.
“Guselkumab, a monoclonal antibody that selectively inhibits interleukin (IL)-23 p19, was the first agent in its class approved for patients with active PsA,” Proton Rahman, MD, FRCPC, of the Craig L. Dobbin Genetics Research Center at Memorial University of Newfoundland, in Canada, and colleagues wrote. “The majority of these patients were